+44 (0)1865-842-976 (UK)

+91 20 30108 270 (ASIA)

Translation from pre-clinical neuroscience to clinical setting is one of the major setback for the researchers working in Neuroscience R&D. However, considering the recent advances in this field there have been newer technologies coming up in the area of Drug target validation, Neuroimaging, Optogenetics, Neuromodulation and Neuroinformatics using different animal models and approaches.

After our two successful editions, MarketsandMarkets is proud to announce the 3rd Annual Neuroscience R&D Technologies Conference to be held on 28th-29th September 2017 in London, UK. The conference aims to focus on sharing the current market trends, technological advancements and future challenges in the pre-clinical neuroscience research where the leading experts from the pharma industry and research institutes will discuss the latest technologies in Neuroscience R&D by presenting expert keynote presentations, live case studies and breakthrough panel discussions.

Post Show Report 2016

Click here to view post show report of 2nd Annual Neuroscience R&D Technologies Conference 2016.

conference Registration Form



Academic Delegate£399
Industry Delegate £499
Solution Provider Delegate£995


Key Highlights:

  • Drug target validation technologies in CNS drug discovery
  • Translational Imaging technologies-EEG, EMG, FMRI for assessment of CNS function
  • Optogenetic tools used in brain mapping
  • Novel neuroprostheses and neuromodulation for treating CNS disorders
  • Translational animal models for CNS disorders
  • Neuroinformatics and Computational Neuroscience

Who Should Attend ?

From Pharmaceutical, Academics and Research Institutes

Chief Scientific Officer/Directors/Heads/VP/Managers/Senior Scientists/ Principal/ Scientist/ Neuroscientists/ Project Leaders/ Professors/Research Fellows in:

  • Neuroscience/CNS drug discovery
  • Translational Neuroscience
  • Pre-clinical research
  • Computational Neuroscience/Neuroinformatics
  • Neurotechnology
  • Neuroimaging/Translational Imaging
  • Neurodegenerative diseases
  • Neuroengineering
  • Neuropharmacology/Neurobiology
  • Neuromorphic engineers

Why Attend?

  • First ever conference on application of technology in developing neurological treatments 
  • Meet global heads of neuroscience from the industry and Academics
  • 100+ neuroscience professionals attending
  • Access to online presentations on-demand post-summit
  • Case studies presented from leading technology collaborations 
  • Interactive panel and breakout sessions

Advisory Panel

  • Dr. Janet Nicholson
    Director, CNS Diseases Research
    Boehringer Ingelheim, Germany

  • Thomas Jahn
    Lab Head, Neuroscience Discovery
    AbbVie, Germany

  • Kei Cho
    Chair of Neuroscience, MRC Centre for Synaptic Plasticity
    University of Bristol, UK

  • Michela Chiappalone
    Scientific Investigator
    Italian Institute of Technology (IIT), Italy


  • Janet Nicholson

    Director, CNS Diseases Research Boehringer Ingelheim, Germany
  • Thomas Jahn

    Lab Head, Neuroscience Discovery, AbbVie, Germany
  • Kei Cho

    Chair of Neuroscience, MRC Centre for Synaptic Plasticity University of Bristol, UK
  • Michela Chiappalone

    Scientific Investigator Italian Institute of Technology (IIT), Italy
  • Paul Karila

    VP of Discovery Services, Cellectricon, Sweden
  • Mimoun Azzouz

    Chair in Translational Neuroscience, University of Sheffield, UK
  • Frank Hirth

    Group Leader Neural Circuits and Behaviour King’s College London, UK
  • Keith Wafford

    Research Advisor Eli Lilly, UK
  • Amin Hajitou

    Deputy Head, Neuroinflammation & Degeneration Center Imperial College London, UK
  • Bill Martin

    CSO, Head, R&D BlackThorn Therapeutics, USA
  • John Schetz

    Professor of Pharmacology & Neuroscience University of North Texas Health Science Center, USA
  • Silvia Gatti-McArthur

    Head, Research & Development CNS Innovation Center Pierre Fabre, France
  • Simon Schultz

    Director, Neurotechnology, Imperial College London, UK
  • Andreas Koepke

    Chief Business Officer SynAging, Germany
  • Dirk Schubert

    Assistant Professor Cellular Neurophysiology Radboud University Nijmegen Medical Centre, Netherlands
  • Jean-Pierre Mothet

    Director of Research, CNRS, France
  • Markus Kaiser

    Professor of Neuroinformatics, Newcastle University
  • Neil Cashman

    Professor, Neuroscience, University of British Columbia
  • Sandra Robelet

    Chief Scientific Officer, Syncrosome
  • Bruno Buisson

    General Manager, Chief Scientist Neuroservice, France
  • Caroline Louis

    Director, Experimental Neuroscience Research Servier, France
  • Daniel Haag

    Chief Scientific Officer, NeuCyte Inc,USA
  • Dietmar Hess

    Product Manager, Neural Cells, Support & Application Ncardia, Germany


Silver Sponsor

Cellectricon ABCellectricon AB

Cellectricon is a leading provider of advanced cell-based screening services to accelerate drug discovery. Exploiting our cutting edge Cellaxess® Elektra platform for functional screening and compound profiling in primary cells and stem cells, our services offering is targeting chronic pain and CNS disease discovery. Our services help researchers identify compound effects in highly relevant biological models early enough in a project’s lifecycle to add real decision-making value.



Ncardia believes that stem cell technology will help to get better medicines to patients faster. The company develops, produces and commercializes highly predictive human cellular assay systems for safety and efficacy testing. The cardiac product portfolio encompasses a broad panel of hiPSC derived Cardiomyocytes (Pluricyte®, Cor.4U® and vCor.4U®) as well cardiac fibroblasts (FibroCor.4U®). In addition, the company delivers the CardioplateTM product line of quality controlled ready to use assay plates. The neural cell portfolio contains the pan-neuronal product CNS4U, the peripheral neurons product Peri.4U®, and astrocyte product Astro.4U®.

Ncardia is based in Belgium, The Netherlands, Germany and in the USA. The company is privately held and established following the merger of Pluriomics and Axiogenesis.




Horizon Discovery

Horizon Discovery

Horizon Discovery combines deep scientific experience in translational research with a precision gene-editing platform incorporating rAAV, CRISPR and ZFN technologies.  Horizon supplies genetically-defined cell lines, in vivo models, custom cell line generation, molecular reference standards, and contract research services to over 1,000 academic, clinical and biopharmaceutical organizations.

NeuroSys - Sponsor - 3rd Annual Neuroscience R&D Technologies Conference


Neuro-Sys, specialized in pharmacology, in vitro models for neurodegenerative diseases and High Content  Imaging, provides its strong expertise to evaluate therapeutic molecules for Efficacy (E-FORM®) / Mode of action (MOAFORM®), from hit to drug candidate and repositioning projects:

  • Alzheimer’s & Parkinson’s  Disease (acute & chronic)
  • Multiple Sclerosis
  • Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease)
  • Charcot Marie Tooth
  • Peripheral neuropathies
  • Blood Brain Barrier (Healthy / AD/PD)


SAS SynAging

SynAging SAS is a CRO providing Drug Discovery Service for Proteinopathic Neurodegenerative Diseases, like AD and PD.

Recently it became evident that soluble misfolded-protein-oligomers play a pivotal role in the formation of neurodegenerative diseases. SynAging produces such oligomers of human: amyloid-β, tau and α-synuclein with unmatched reproducibility. Oligomeric preparations are used in vitro on rodent and human neurons and in vivo in WT mice, to induce synaptic loss, cognitive decline, and neuroinflammation.

•  Disease relevant models
•  Robust assays with highest reproducibility
•  More results faster
•  Cost-effective


As more than 60% of new drugs fail in phase 2, we have chosen to focus our activities since 2000 on preclinical in Vivo Efficacy Studies to offer better predictability and anticipate clinical results.

Syncrosome offer relevant disease models, cutting-edge techniques, specific Biomarkers and a comprehensive background of physiopathology to assist drug discovery companies in selecting their compounds.

Our main activities consit in:

  • In vitro Drug Efficacy Studies for: Central Nervous System with models in Parkinson, Alzheimer and Stroke disease.
  • In vivo Drug Efficacy Studies for:
  • Central Nervous System,
  • Cardiovascular and Metabolic disease,
  • Respiratory,
  • Gastroenterology


Neuroservice is a private Contract Research Organization providing pharmacological assays based on electrophysiological recordings of acute brain slices, spinal cord slices, human brain slices and cultured neurons. These assays are performed with two complementary techniques: the Multi-Electrode Array and the Patch-Clamp. The mission of Neuroservice is to support the early phases of CNS and PAIN R&D programs in Lead Selection & Optimization as well as in the investigation of Mechanism of Action for experimental compounds.


Key-Obs is a preclinical Contract Research Organisation (CRO) specialized in central nervous system in vivo pharmacological studies and behavioral phenotyping of transgenic rodents. Key-Obs offers in vivo models and screening assays in the fields of psychiatry, neurodegenerative, neurodevelopmental and rare diseases. Our models are well validated, we also customize models and tests to your specific needs.Key-Obs works for major pharmaceutical and Biotech companies all over the world, as well as academic partners.

NEUCYTE NeuCyte Inc.

NeuCyte Inc.
is a biotechnology company focusing on early phases of CNS drug discovery.  Based on our SynFire
TM technology, we have developed a proprietary human neural in vitro platform for complex electrophysiological and morphological readouts suited for target identification and validation, efficacy testing and neurotoxicity assessment. Using patient-derived and genetically engineered defined neural cell types, NeuCyte builds unique cell-based assays for modelling neurological and neurodegenerative disorders.

Sponsorship Opportunity
MarketsandMarkets provides a variety of direct and indirect marketing and networking opportunities for sponsors and exhibitors. 


All refreshment breaks and lunches take place in the main exhibition ensuring that exhibitors enjoy maximum time to meet and network with senior level attendees. 

Speaking and Workshop Opportunities

  • 15 minute small company showcase presentations.
  • 30 minute presentations on the main conference programme.
  • 25 minute satellite symposiums.
  • 60 minute presentation / workshop on the main conference programme.

Please enquire for pre and post events workshop options. 

Pre-arranged One-on-Meetings

Prearranged one-on-one meetings ensure that you have personal time with your choice of delegates. Twenty minute meetings take place during refreshment breaks. Full delegate profiles are provided prior to the conference to ensure that onsite, you meet with relevant delegates who are truly interested in your products and services. Meetings can take place on your exhibition or in your own private meeting area. 

Pre-event Support

MnM Conferences provide full service pre-event marketing and branding support. Opportunities available include: 

  • Your logo and company description on the event website.
  • Your logo on all marketing materials as a sponsor.
  • Pre-event email shots to attending delegates to increase your onsite exposure.
  • Articles about your products and services in our monthly event newsletter.

For sponsorship opportunities please contact us at events@marketsandmarkets.com


All Poster presentations will take place in breaks and alongside the breakout sessions of the congress.  All the presentation will be displayed in a dedicated area along with accepted posters from both industry & vendor delegates.

To present a poster the presenter should be registered as a delegate and the poster space will be assigned on a first come first basic (Subjected to successful registration & space availability)In order to present a poster at the forum you need to be registered as a delegate.

Please note that there is limited space available and posters space is assigned on a first come first served basis (subject to checks and successful registration).

Posters should be presented as A0 or US equivalent, size E (841mm x 1189mm or 34 x 44 inches respectively) in portrait orientation.

Poster presentations are available to registered delegates only.

For further details and requirements please contact:

Email: events@marketsandmarkets.com

Academic delegatesFree
Industry and Solution Provider delegates£75

Posters Submission Form



European Society for Neurochemistry

European Society for Neurochemistry (ESN)

The European Society for Neurochemistry (ESN) was founded in 1976 with the objectives to advance Neurochemistry for the public benefit and to promote the development of Neurochemistry in Europe. ESN is a sister society of the International Society for Neurochemistry (ISN) and a member of Federation of European Neuroscience Societies (FENS). Information about the ESN initiatives you can find at http://www.neurochemsoc.eu. To be ESN member,please fill the application at http://www.neurochemsoc.eu/membership/esn.html and become member of ESN, ISN and FENS with one single application.

The International Federation of Clinical Neurophysiology (IFCN)International Federation of Clinical Neurophysiology (IFCN)

The International Federation of Clinical Neurophysiology (IFCN) has members operating in 59 countries globally. The main goal of the IFCN is to promote education and the highest level of practice of Clinical Neurophysiology to improve health.



NEUROMODEC is a free online service created to support the development of neuromodulation through the integration of shared resources, research tools, professional standards, events and inter-institution collaboration. Consistent with our mission to freely disseminate information, Neuromodec.com serves to advance neuromodulation basic research, technologies and the clinical implementation of the associated therapies.


BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences, and companies are assisted with access to government grants and heavily discounted entry fees. Through the BioPartnership Programme, members receive extra benefits and support to effectively trade overseas.



3rd Annual Neuroscience R&D Technologies Conference will be held at the Radisson Blu Edwardian Heathrow Hotel in London, UK.

Radisson Blu Edwardian Heathrow Hotel
Heathrow Airport
140 Bath Road, Hayes
Middlesex  UB3 5AW  England
LAT: 51.481529 LONG: -0.441432

Hotel Booking Link

Accommodation is currently available at the Radisson Blu Edwardian Heathrow Hotel at discounted rate. You will receive a link to book your accommodation via once you are fully registered. (Please note that we do not authorize any 3rd party agencies (e.g. Exhibitors Housing Management) to book on our behalf and, occasionally, companies fraudulently try to represent us. If you are contacted by anyone other than us regarding your accommodation requirements for this event, please let us know immediately on events@marketsandmarkets.com).

About the Hotel

Minutes from Heathrow, Radisson Blu Edwardian, Heathrow is a 4 star airport hotel that feels like anything but. Dramatic spaces, distinctive design and dedicated service come together in a location where London meets the world. Rooms are spacious and deeply comfortable, and expansive spaces are ideal for entertaining and events on a grand scale. A buzzing Bijou Bar, new Steak & Lobster dining experience, Indian restaurant Annayu and soothing Pegasus Spa make this hotel perfect for work or play, and the ‘Stay, Park and Fly’ package gives you complimentary airport parking when you fly from Heathrow.

For further Information, please contact:
Email: events@marketsandmarkets.com